NextPlat Corp

NextPlat Corp announced the completion of its strategic acquisition of an independent pharmacy in the Pensacola area of northwest Florida for $1,485,439 in cash. The acquired pharmacy generated approximately $5.6 million in sales in 2025 and was profitable with a debt-free balance sheet. This acquisition is expected to enhance NextPlat's pharmacy diversification, accelerate healthcare growth, and contribute to the profitability of its PharmcoRx segment by introducing high-value services to the region.

NextPlat Corp reported significantly improved operating results for the second quarter ended June 30, 2026. The company achieved a 21% sequential increase in consolidated revenue to $11.9 million and reduced its net loss by 87% to $0.1 million. Gross margin reached a record 40%, driven by a strategic shift towards higher-margin 340B contracted pharmacy services, which saw a 136% year-over-year revenue increase. NextPlat also announced a planned acquisition of a pharmacy operation and the upcoming launch of a nationwide medication fulfillment website.

NextPlat Corp announced that its indirect subsidiary, Progressive Care, LLC, entered into an agreement to acquire 100% of Scott's Pharmacy, LLC, a community pharmacy in Molino, Florida. The acquisition is valued at $1.5 million in cash and is expected to close by September 30, 2026. Scott's Pharmacy generated approximately $5.6 million in sales in 2025 with 19% retail margins, and the acquisition will expand NextPlat's PharmcoRx retail footprint and introduce new healthcare services in the region.

NextPlat Corp held its 2026 Annual Meeting on June 24, 2026, where stockholders approved all matters submitted for a vote. This included the election of six director nominees, the ratification of RBSM LLP as the independent registered public accounting firm for 2026, and the advisory approval of named executive officer compensation. Approximately 62.23% of the outstanding shares participated in the voting.

NextPlat Corp reported a net loss of $(1.12) million for Q1 2026, a significant improvement from $(1.94) million in Q1 2025. However, total revenue decreased by 29% to $9.86 million. The company also completed a 1-for-10 reverse stock split and regained Nasdaq compliance, while establishing an At-the-Market offering program for up to $3.74 million. Management continues to address going concern doubts through operational plans and capital access.

NextPlat Corp reported Q1 2026 revenue of $9.9 million, a 29% decrease year-over-year, primarily due to lower healthcare prescription revenue. Despite the revenue decline, the company achieved a record consolidated gross margin of 35% and reduced total operating expenses by 9% to $4.5 million, leading to a 42% decrease in net loss to $1.1 million. Management expects to achieve positive operating income in the latter half of 2026, driven by higher-margin contracted healthcare services and continued expense controls.

NextPlat Corp (NXPL) announced its Annual Meeting of Stockholders will be held virtually on June 24, 2026, with April 27, 2026, as the record date for voting. Key proposals include the election of six directors, ratification of RBSM LLP as the independent auditor for 2026, and an advisory vote on executive compensation. The company also noted a 1-for-10 reverse stock split effective April 13, 2026.

NextPlat Corp announced it has regained compliance with Nasdaq's minimum bid price requirement. The company had previously received a notice on April 28, 2025, for failing to maintain a $1.00 closing bid price for 30 consecutive trading days. After being granted a second 180-day grace period until April 27, 2026, Nasdaq confirmed on April 27, 2026, that the company is now compliant, closing the matter.

NextPlat Corp (NXPL) announced a 1-for-10 reverse stock split, effective April 13, 2026. The reverse stock split will reduce the number of outstanding shares from approximately 26.9 million to approximately 2.7 million, while the number of authorized shares will remain at 50 million. This action is often taken to increase the stock price and potentially attract institutional investors or meet listing requirements.